^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:Cejemly (sugemalimab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    CStone Pharma Press Release
    Title:

    CS1001 Plus Chemotherapy Shows Significant PFS Prolongation in Stage IV NSCLC

    Published date:
    08/06/2020
    Excerpt:
    In the overall population containing both squamous and non-squamous NSCLC patients, investigator-assessed PFS HR (95% CI) was 0.50 (0.39, 0.64), p<0.0001. The median PFS was 7.8 months vs. 4.9 months in CS1001 combined with chemotherapy and placebo combined with chemotherapy, respectively...Subgroup analyses showed clinical benefit across histology subtypes and PD-L1 expression levels...
    Trial ID:
    GEMSTONE302
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

    Excerpt:
    ...Progression-free survival (PFS) in subjects with PD-L1≥ 1% and PFS in all subjects evaluated by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1...
    Trial ID:
    GEMSTONE302